Pre-made Brentuximab Vedotin benchmark antibody (Whole mAb ADC, anti-TNFRSF8 therapeutic antibody, Anti-CD30/D1S166E/Ki-1 Antibody) for drug discovery and mechanism of action (MOA) research

Pre-made Brentuximab Vedotin benchmark antibody (Whole mAb ADC, anti-TNFRSF8 therapeutic antibody, Anti-CD30/D1S166E/Ki-1 Antibody) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Brentuximab vedotin (INN; trade name Adcetris) is an antibody-drug conjugate medication used to treat relapsed or refractory Hodgkin lymphoma (HL) and systemic anaplastic large cell lymphoma (ALCL), a type of T cell non-Hodgkin lymphoma. It selectively targets tumor cells expressing the CD3 antigen, a defining marker of Hodgkin lymphoma and ALCL.[2] The drug is being jointly marketed by Millennium Pharmaceuticals outside the US and by Seattle Genetics in the US.[3]

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	Price(In USD)	Qty (Quantity)	Sum(In USD)
GMP-Bios-INN-765-1mg	1mg	4635
GMP-Bios-INN-765-10mg	10mg	Inquiry
GMP-Bios-INN-765-100mg	100mg	Inquiry
GMP-Bios-INN-765-xmg	≥100mg	Inquiry
			Shipping Cost:	760.00
			Total:

Description

Products Name (INN Index)	Pre-Made Brentuximab Vedotin Biosimilar, Whole Mab Adc, Anti-Tnfrsf8 Antibody: Anti-CD30/D1S166E/Ki-1 therapeutic antibody Drug Conjugate
INN Name	Brentuximab Vedotin
Target	TNFRSF8
Format	Whole mAb ADC
Derivation	Chimeric
Species Reactivity	human
CH1 Isotype	IgG1 - kappa
VD LC	IgG1 - kappa
Highest_Clin_Trial (Jan '20)
Est. Status
100% SI Structure
99% SI Structure
95-98% SI Structure
Year Proposed
Year Recommended
Companies	Seattle genetics, Inc. (Bothell WA USA) / Takeda Pharmaceutical Co. Ltd. (Osaka Japan)
Conditions Approved
Conditions Active
Conditions Discontinued
Development Tech	0